Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 14/20 | 0.81 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 6/20 | 0.81 |
| ▸ | PRKCG | P05129 | 6/20 | 0.81 |
| ▸ | PRKCZ | Q05513 | 6/20 | 0.81 |
| ▸ | PRKCA | P17252 | 6/20 | 0.81 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.81 |
| ▸ | PRKCB | P05771 | 5/20 | 0.81 |
| ▸ | PRKCH | P24723 | 5/20 | 0.81 |
| ▸ | PRKCI | P41743 | 5/20 | 0.81 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.81 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.81 |
| ▸ | EGFR | P00533 | 4/20 | 0.81 |
| ▸ | PRKACA | P17612 | 4/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.81 |
| ▸ | KDR | P35968 | 3/20 | 0.81 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.81 |
| ▸ | SRC | P12931 | 3/20 | 0.81 |
| ▸ | PRKACG | P22612 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12253229 | 1.00 | PRKCQ (0.81) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL12253230 | 1.00 | PRKCQ (0.81) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL22765429 | 0.92 | PRKCQ (0.83) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL29884772 | 0.92 | PRKCQ (0.83) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL638600 | 0.92 | PRKCQ (0.83) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL14822686 | 0.89 | PRKCQ (0.79) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| Staurosporine SCHEMBL23793206 | 0.89 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| Staurosporine SCHEMBL14264595 | 0.89 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| Staurosporine SCHEMBL13659665 | 0.89 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCZ | |
| SCHEMBL24393902 | 0.89 | PRKCQ (1.00) | PRKCQROCK2PRKD3PRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180008273-A1 | EMBOLIC COILS AND RELATED COMPONENTS, SYSTEMS, AND METHODS | BOSTON SCIENTIFIC SCIMED, INC. | 2018-01-11 | — | — | US | disclosed |
| US-9795389-B2 | Embolic coils and related components, systems, and methods | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9750695-B2 | Cross-linked polymer particles | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160296235-A1 | MEDICAL DEVICES | BOSTON SCIENT SCIMED INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9314551-B2 | Block copolymer-coated endoprosthesis | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9283035-B2 | Tissue-treatment methods | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9050092-B2 | Embolic coils | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8992993-B2 | Cross-linked polymer particles | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140088669-A1 | PARTICLES | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130224487-A1 | CROSS-LINKED POLYMER PARTICLES | BOSTON SCIENTIFIC SCIMED, INC. | 2013-08-29 | — | — | US | disclosed |
| US-8430105-B2 | Tissue-treatment methods | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120215297-A1 | EMBOLIC COILS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120195951-A1 | Therapeutic Inhibitor of Vascular Smooth Muscle Cells | KUNZ LAWRENCE L (US) | 2012-08-02 | — | — | US | disclosed |
| US-8067022-B2 | Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110282430-A1 | Endoprosthesis | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110213358-A1 | Tissue-Treatment Methods | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088669-A1 | PARTICLES | APOB, HDLBP, NASP | PRKCQ 3002/4885ROCK2 4174/4885PRKD3 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.